BACKGROUND: There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. METHODS: The medical charts of 180 patients with advanced chondrosarcomas having received chemotherapy in 15 participating institutions between 1988 and 2011 were reviewed. RESULTS: Median age was 52 years. Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Combination chemotherapy was delivered in 98 cases (54.5%). One hundred and thirty-one patients (73%) received an anthracycline-containing regimen. Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P = 0.04). Median progression-free survival (PFS) was 4.7 months [95% confidence interval (CI) 3-6.5]. Performance status (PS) ≥2, number of metastatic sites ≥1 and single-agent regimen were independently associated with poor PFS. Median overall survival (OS) was 18 months (95% CI 14.5-21.6). PS, number of metastatic sites and palliative surgery were independently associated with OS. CONCLUSIONS: Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.
BACKGROUND: There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. METHODS: The medical charts of 180 patients with advanced chondrosarcomas having received chemotherapy in 15 participating institutions between 1988 and 2011 were reviewed. RESULTS: Median age was 52 years. Sixty-three percent of patients had conventional chondrosarcoma and 88% had metastatic disease. Combination chemotherapy was delivered in 98 cases (54.5%). One hundred and thirty-one patients (73%) received an anthracycline-containing regimen. Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma (P = 0.04). Median progression-free survival (PFS) was 4.7 months [95% confidence interval (CI) 3-6.5]. Performance status (PS) ≥2, number of metastatic sites ≥1 and single-agent regimen were independently associated with poor PFS. Median overall survival (OS) was 18 months (95% CI 14.5-21.6). PS, number of metastatic sites and palliative surgery were independently associated with OS. CONCLUSIONS: Conventional chemotherapy have very limited efficacy in patients with advanced chondrosarcoma, the highest benefit being observed in mesenchymal and dedifferentiated chondrosarcoma. These data should be used as a reference for response and outcome in the assessment of investigational drugs in advanced chondrosarcoma.
Authors: Anne-Marie Cleton-Jansen; Hetty M van Beerendonk; Hans J Baelde; Judith V G M Bovée; Marcel Karperien; Pancras C W Hogendoorn Journal: Clin Cancer Res Date: 2005-11-15 Impact factor: 12.531
Authors: J G van Oosterwijk; B Herpers; D Meijer; I H Briaire-de Bruijn; A M Cleton-Jansen; H Gelderblom; B van de Water; J V M G Bovée Journal: Ann Oncol Date: 2011-11-23 Impact factor: 32.976
Authors: K Antman; J Crowley; S P Balcerzak; S E Rivkin; G R Weiss; A Elias; R B Natale; R M Cooper; B Barlogie; D L Trump Journal: J Clin Oncol Date: 1993-07 Impact factor: 44.544
Authors: E C Borden; D A Amato; C Rosenbaum; H T Enterline; M J Shiraki; R H Creech; H J Lerner; P P Carbone Journal: J Clin Oncol Date: 1987-06 Impact factor: 44.544
Authors: A Italiano; A Le Cesne; C Bellera; S Piperno-Neumann; F Duffaud; N Penel; P Cassier; J Domont; N Takebe; M Kind; J-M Coindre; J-Y Blay; B Bui Journal: Ann Oncol Date: 2013-11 Impact factor: 32.976
Authors: Frank M Klenke; Amir Abdollahi; Elisabeth Bertl; Martha-Maria Gebhard; Volker Ewerbeck; Peter E Huber; Axel Sckell Journal: BMC Cancer Date: 2007-03-17 Impact factor: 4.430
Authors: Quirina C B S Thio; Aditya V Karhade; Paul T Ogink; Kevin A Raskin; Karen De Amorim Bernstein; Santiago A Lozano Calderon; Joseph H Schwab Journal: Clin Orthop Relat Res Date: 2018-10 Impact factor: 4.176
Authors: Annemiek van Maldegem; Anthony P Conley; Piotr Rutkowski; Shreyaskumar R Patel; Iwona Lugowska; Ingrid M E Desar; Judith V M G Bovée; Hans Gelderblom Journal: Oncologist Date: 2018-08-06
Authors: J D Palmer; M E Gamez; K Ranta; H Ruiz-Garcia; J L Peterson; D M Blakaj; D Prevedello; R Carrau; A Mahajan; K L Chaichana; D M Trifiletti Journal: J Neurooncol Date: 2020-08-12 Impact factor: 4.130